Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

$24.99

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Pfizer Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in millions

Microsoft Excel
Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021
Short-term borrowings, including current portion of long-term debt
Trade accounts payable
Dividends payable
Income taxes payable
Accrued compensation and related items
Other current liabilities
Current liabilities
Long-term debt, excluding current portion
Pension and postretirement benefit obligations
Noncurrent deferred tax liabilities
Other taxes payable
Other noncurrent liabilities
Noncurrent liabilities
Total liabilities
Common stock
Additional paid-in capital
Treasury stock
Retained earnings
Accumulated other comprehensive loss
Total Pfizer Inc. shareholders’ equity
Equity attributable to noncontrolling interests
Total equity
Total liabilities and equity

Based on: 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04).


The overall financial structure exhibits a significant expansion in total liabilities and equity, growing from 158.8 billion USD in April 2021 to a peak of 226.5 billion USD in December 2023, before stabilizing around 207.6 billion USD by March 2026. This growth is primarily driven by a substantial increase in long-term debt and a corresponding shift in the company's capital composition.

Long-Term Debt and Noncurrent Liabilities
A pivotal shift in the capital structure occurred in July 2023, where long-term debt, excluding the current portion, jumped from approximately 31.7 billion USD to 61.4 billion USD. This elevated level of debt remained relatively constant, fluctuating between 57.4 billion USD and 61.6 billion USD through March 2026. Consequently, noncurrent liabilities rose from a range of 58 billion to 63 billion USD in the 2021-2022 period to a higher plateau between 79 billion and 89 billion USD from 2023 onwards.
Current Liabilities and Short-Term Obligations
Current liabilities showed significant volatility, peaking at 47.8 billion USD in December 2023. Short-term borrowings experienced sharp fluctuations, notably spiking to 11.9 billion USD in June 2024 before decreasing to 3.9 billion USD by March 2026. Other current liabilities remained a substantial component of the short-term profile, generally fluctuating between 17 billion and 28 billion USD throughout the analyzed period.
Shareholders' Equity and Retained Earnings
Total equity experienced a period of growth, rising from 68.9 billion USD in April 2021 to a peak of 101.2 billion USD in April 2023. Following this peak, equity entered a phase of moderate decline and stabilization, ending at 90.4 billion USD in March 2026. Retained earnings followed a similar trajectory, peaking at 131.1 billion USD in April 2023 before contracting to 117.2 billion USD by the end of the period.
Capital Management and Treasury Stock
A consistent increase in the magnitude of treasury stock is observed, moving from negative 111.3 billion USD in April 2021 to negative 115.2 billion USD in March 2026. This indicates a sustained commitment to share repurchases. Additionally, accumulated other comprehensive loss widened from 4.7 billion USD in early 2021 to a peak of 8.6 billion USD in March 2024, before recovering slightly to 7.2 billion USD by March 2026.
Total Liability and Equity Trends
The total balance sheet expanded by approximately 30% between April 2021 and March 2026. While the initial growth was balanced between equity and liabilities, the later stages of the period were characterized by a higher reliance on long-term debt to sustain the expanded asset base, as evidenced by the stabilization of total equity at levels below its 2023 peak despite the overall increase in total liabilities.